Core Viewpoint - Huyou Pharmaceutical has received approval from the U.S. FDA for its new drug applications for Etoposide Injection and Fluorouracil Injection, allowing the company to produce and sell these products in the U.S. market [1] Group 1 - The approval from the U.S. FDA signifies that the company is now qualified to sell products in the U.S. market [1] - This development is expected to help the company expand its sales in the U.S. market and strengthen its product supply chain [1] - The approval also enriches the company's product portfolio and lays a solid foundation for sustainable development in international markets [1]

Group 1: Financial Performance Highlights - Lante Optics achieved a revenue of 1.536 billion yuan in 2025, a year-on-year increase of 48.52%, with a net profit of 388 million yuan, up 76.09% [1] - United Imaging reported a revenue of 13.82 billion yuan for 2025, reflecting a 34.18% year-on-year growth, and a net profit of 1.888 billion yuan, up 49.60% [2] - Hengxuan Technology's revenue reached 3.525 billion yuan, an 8.02% increase, with a net profit of 588 million yuan, up 27.75% [3] - Nanya New Materials reported a significant net profit increase of 378.65%, reaching 241 million yuan, with revenue of 5.228 billion yuan, up 55.52% [4] - Yancoal Australia, a subsidiary of Yancoal Energy, reported a revenue of 5.949 billion AUD and a net profit of 4.4 billion AUD for 2025 [5] - Hanlan Co. reported a revenue of 10.467 billion yuan, a 13.04% increase, but a net profit decline of 9.59% to 592 million yuan [10][11] - Transsion Holdings experienced a revenue decline of 4.50% to 65.623 billion yuan, with a net profit drop of 53.43% to 2.584 billion yuan [14] - Huachuang Technology achieved a revenue of 628 million yuan, a 2.78% increase, with a net profit of 42.678 million yuan, up 89.45% [21] - Aiko Optoelectronics reported a revenue of 440.311 million yuan, a 77.36% increase, with a net profit of 64.0919 million yuan, up 307.63% [34] - Chip Microelectronics achieved a revenue of 1.408 billion yuan, a 47.61% increase, with a net profit of 290 million yuan, up 80.42% [35] - Shenkong Co. reported a revenue of 443 million yuan, a 46.26% increase, with a net profit of 101 million yuan, up 146.54% [36] - Qinda Environmental reported a revenue of 2.042 billion yuan, a 55.42% increase, with a net profit of 181 million yuan, up 94.62% [39] Group 2: Corporate Developments - Huilong New Materials announced that its actual controller is planning a significant matter that may lead to a change in company control, resulting in a stock suspension [6] - Fangzheng Securities disclosed that its shareholder China Cinda did not reduce its shareholding as planned during the designated period [7] - Lingyi Technology plans to invest 20 million yuan in a partnership with several investment firms [8] - Longbai Group's subsidiary has partially resumed production after a safety incident [9] - Fuda Co. plans to reduce its repurchased shares by up to 1% through centralized bidding [13] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for lung cancer [15] - Beixin Road and Bridge won a bid for a highway reconstruction project worth 751 million yuan [16] - Songsheng Co. established a joint venture with a registered capital of 30 million yuan, focusing on digital energy products [17] - Moxinlin reported a revenue of 577 million yuan, a 20.98% increase, with a net profit of 55.8745 million yuan, up 22.69% [18] - Zhuhai Beer reported a revenue of 5.878 billion yuan, a 2.56% increase, with a net profit of 903 million yuan, up 11.42% [24] - Honghua Digital reported a revenue of 2.308 billion yuan, a 28.90% increase, with a net profit of 529 million yuan, up 27.63% [25] - Xinfeng Pharmaceutical received FDA approval for two injectable drugs [26] - Jiazhe New Energy's project for green hydrogen production received regulatory approval [27] - Chip Microelectronics reported a revenue of 5.24 billion yuan, a 29.48% increase, with a net profit of 302 million yuan, up 36.1% [28] - Debang Co. completed the cash settlement process for its delisting [29] - Xingfu Electronics reported a revenue of 1.475 billion yuan, a 29.72% increase, with a net profit of 208 million yuan, up 30.37% [30] - Longda Food announced the resignation of its general manager due to work adjustments [31] - Bohai Chemical reported that some fundraising projects have commenced production [32] - Shengke Communication reported a net loss of 150 million yuan for 2025 [33] - Jin Cheng Pharmaceutical's subsidiaries received drug registration certificates for two products [37] - Jinpu Titanium Industry announced the resumption of production at its subsidiary [38] - Zhigao Electric's subsidiary won a bid for a project worth 182 million yuan [40]

自愿披露依托泊苷注射液、氟尿嘧啶注射液 获得美国 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）于近日收到美国食品药品 监督管理局（以下简称"美国 FDA"）的通知，公司向美国 FDA 申报的依托泊 苷注射液、氟尿嘧啶注射液的新药申请（NDA）均已获得批准，意味着公司可 以生产并通过海外合作方在美国市场销售前述产品。现将相关情况公告如下： 证券代码：688553 证券简称：汇宇制药 公告编号：2026-010 四川汇宇制药股份有限公司 一、药品基本情况 （一）依托泊苷注射液 公司已开展产品上市销售的前期准备工作，同时受产品的非唯一性、同类产 品竞争以及未来公司业务的推广效果、销售规模等因素影响，未来能否产生较大 收入具有较大不确定性。产品注册批件的取得在短期内对公司经营业绩不构成重 大影响。敬请广大投资者谨慎决策，注意防范投资风险。 二、药品的其他相关情况 依托泊苷注射液是一种拓扑异构酶抑制剂，与其它化疗和/或免疫治疗联合 使用，适用于治疗以下成年患者： 1 ...

Core Viewpoint - The company, Huyou Pharmaceutical (688553.SH), has received approval from the U.S. FDA for its new drug applications (NDA) for Etoposide Injection and Fluorouracil Injection, allowing it to produce and sell these products in the U.S. market [1] Group 1: Product Approvals - Etoposide Injection is a topoisomerase inhibitor used in combination with other chemotherapy and/or immunotherapy treatments for adult patients with refractory testicular cancer and small cell lung cancer [1] - Fluorouracil Injection is indicated for the treatment of colon cancer, rectal cancer, breast cancer, gastric adenocarcinoma, and pancreatic cancer [1] Group 2: Market Expansion - The FDA approval signifies the company's eligibility to sell products in the U.S. market, which will help expand its sales in the U.S., strengthen its product supply chain, and enrich its product portfolio [1] - This development lays a solid foundation for the sustainable growth of the company in international markets [1]

Core Viewpoint - Huiyu Pharmaceutical (688553.SH) has received approval from the U.S. FDA for its new drug applications (NDA) for Etoposide Injection and Fluorouracil Injection, enabling the company to sell products in the U.S. market [1] Group 1 - The approval marks a significant milestone for the company, allowing it to expand its sales in the U.S. market [1] - This development strengthens the company's product supply chain and enriches its product portfolio [1] - The approval lays a solid foundation for the sustainable development of the company in international markets [1]

Group 1 - The company, Sichuan Huiyu Pharmaceutical Co., Ltd., successfully passed the FDA's current Good Manufacturing Practice (cGMP) inspection and Pre-Approval Inspection (PAI) conducted from October 27, 2025, to November 6, 2025 [1] - The inspection covered the production of active pharmaceutical ingredients, sterile active pharmaceutical ingredients, small-volume injections, lyophilized powder, and sterile powders [1] - The FDA issued a Voluntary Action Indicated (VAI) conclusion, indicating that the company needs to take voluntary corrective actions [1] Group 2 - This inspection marks the third time the company has undergone an FDA inspection, confirming that its production lines for anti-tumor injectables and active pharmaceutical ingredients meet FDA requirements [1] - The successful inspection is expected to positively impact the company's future operating performance and enhance its competitiveness in the international market [1]

Group 1: Key Developments in Technology and Innovation - Elon Musk envisions launching AI satellites from the Moon using electromagnetic catapults to create a satellite network for data centers [4] - Xiaomi plans to focus on core technologies such as chips, AI, and operating systems over the next five years to become a global tech leader [3] - Apple intends to purchase over 100 million advanced chips from TSMC's Arizona factory by 2026 [5] Group 2: Investment and Financial Performance - Hubei province is increasing investments in emerging industries like integrated circuits and embodied intelligence while optimizing real estate investments to boost domestic demand [2] - AMD has agreed to sell AI chips worth up to $60 billion to Meta, which will deploy 6 GW of AMD GPUs [6] - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, a year-on-year increase of 108.05% [9] - Sry New Materials achieved a net profit of 154 million yuan in 2025, reflecting a 35.04% year-on-year growth [12] - Sanofi Guojian reported a net profit of 2.939 billion yuan for 2025, a staggering increase of 317.09% [12] Group 3: Corporate Actions and Strategic Moves - Shenlian Bio plans to acquire a controlling stake in Shizhi Yuan for 237 million yuan to expand into innovative pharmaceuticals [8] - Kaipu Cloud terminated its acquisition of Nanning Taike due to market changes and lack of agreement on key terms [8] - Senno Medical's subsidiary received EU CE MDR certification for its Ghunter intracranial thrombectomy stent, enabling entry into the EU market [14] Group 4: Financing and Market Activity - Qianxun Intelligent completed nearly 2 billion yuan in financing, with a valuation exceeding 10 billion yuan [15] - Renxin Technology, a leader in high-speed automotive SerDes chips, completed a strategic round of financing led by SAIC and other industry capital [16]

Core Viewpoint - The company, 汇宇制药 (688553.SH), successfully passed the FDA's current Good Manufacturing Practice (cGMP) inspection and Pre-Approval Inspection (PAI), which is crucial for its operations in the U.S. market [1] Group 1 - The FDA conducted inspections from October 27, 2025, to November 6, 2025, and the company received the Establishment Inspection Report (EIR) confirming the completion of the inspection [1] - This inspection marks the third time the company has undergone an FDA site inspection, indicating a consistent compliance with regulatory standards [1] - The successful completion of the cGMP and PAI inspections enhances the company's production management quality system and operational compliance, which is essential for expanding its market presence in the U.S. [1] Group 2 - The positive outcome of the inspections is expected to have a favorable impact on the company's future operating performance and improve its competitiveness in international markets [1] - The inspections provide a solid foundation for the company's ongoing and healthy development in the pharmaceutical industry [1]

Core Viewpoint - The company, Huyou Pharmaceutical, successfully passed the FDA's current Good Manufacturing Practice (cGMP) inspection and Pre-Approval Inspection (PAI), which is crucial for its operations in the U.S. market [1] Group 1: FDA Inspection Results - The company underwent the FDA inspection from October 27, 2025, to November 6, 2025, and received the Establishment Inspection Report (EIR) confirming the completion of the inspection [1] - This inspection marks the third time the company has been evaluated by the FDA, indicating a consistent compliance with regulatory standards [1] Group 2: Impact on Business Operations - The successful completion of the cGMP and PAI inspections ensures that the company's production lines for anti-tumor injectables and active pharmaceutical ingredients meet FDA requirements [1] - This achievement is expected to positively influence the company's future operating performance and enhance its competitiveness in international markets [1] - The inspection results provide a solid foundation for the company's ongoing expansion in the U.S. market, supporting its sustainable and healthy development [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日至 2025 年 11 月 06 日接受了来自美国食品药品监督管理局（以下简称"FDA"） 的现行药品生产质量管理规范（cGMP）检查和药品批准前检查（PAI）。近日， 公司收到了 FDA 签发的现场检查报告（EIR），该报告表明 FDA 确认本次检查 已结束，公司通过本次 cGMP 检查和药品批准前检查（PAI），现就相关情况公 告如下： 一、FDA 现场检查的相关信息 接受检查企业名称：四川汇宇制药股份有限公司 企业生产地址：四川省内江市市中区汉阳路 333 号 3 幢 检查类别：cGMP 检查和药品批准前检查（PAI） 证券代码：688553 证券简称：汇宇制药 公告编号：2026-009 四川汇宇制药股份有限公司 关于自愿披露通过美国 FDA 现场检查的公告 二、本次检查涉及产品情况 | | | •恶性疾病：恶性淋巴瘤：霍奇金淋巴瘤、 | 间（Ⅳ） | | | --- | --- | -- ...